GlassScriptPhysician profile
Saliaja Gadde
NPI 1871565036
$3,920.61
in general payments reported to CMS, 2019-2025
36 companies · $430 in 2025
The $430 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $389 · 2021: $475 · 2022: $594 · 2023: $646 · 2024: $736 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,626.22 |
| Education | $186.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $441.61 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $389.97 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $264.09 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $247.54 | 2022-2025 | Tagrisso, Imfinzi |
| Daiichi Sankyo INC. | $243.55 | 2020-2024 | Enhertu |
| Seagen INC. | $242.64 | 2019-2023 | Tukysa, Adcetris |
| Regeneron Healthcare Solutions, INC. | $205.55 | 2021-2025 | Libtayo |
| Glaxosmithkline, LLC. | $199.33 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Novartis Pharmaceuticals Corporation | $173.91 | 2019-2023 | |
| Janssen Biotech, INC. | $172.73 | 2019-2024 | Erleada |
| Celgene Corporation | $147.55 | 2021-2025 | Opdualag, Reblozyl, Pomalyst |
| Abbvie INC. | $147.19 | 2019-2024 | |
| Amgen INC. | $144.37 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Eisai INC. | $138.20 | 2020-2025 | |
| Novo Nordisk INC | $121.23 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.74 | 2019-2023 | Gilotrif |
| Array Biopharma INC | $61.74 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $59.13 | 2021-2023 | Imbruvica, Epkinly |
| Incyte Corporation | $53.57 | 2019-2022 | |
| Genentech USA, INC. | $46.90 | 2019-2022 | |
| Clovis Oncology, INC. | $38.03 | 2019 | |
| Global Blood Therapeutics, INC. | $35.69 | 2022 | |
| Genzyme Corporation | $29.50 | 2020-2022 | |
| Gilead Sciences, INC. | $28.51 | 2021-2024 | |
| Beigene USA, INC. | $23.85 | 2023 | Brukinsa |
| Karyopharm Therapeutics INC. | $20.91 | 2020 | |
| Agios Pharmaceuticals, INC. | $20.21 | 2020 | |
| Alexion Pharmaceuticals, INC. | $19.53 | 2024 | Ultomiris |
| Astellas Pharma US INC | $15.97 | 2023 | Padcev |
| Kyowa Kirin, INC. | $15.41 | 2024 | Poteligeo |
| Bayer Healthcare Pharmaceuticals INC. | $15.22 | 2019 | |
| G1 Therapeutics, INC. | $14.88 | 2023 | Cosela |
| Myriad Genetic Laboratories, INC. | $14.80 | 2024 | Myrisk |
| Rigel Pharmaceuticals, INC. | $14.34 | 2019 | |
| Tesaro, INC. | $14.09 | 2019 | |
| Servier Pharmaceuticals LLC | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saliaja Gadde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.